WALTHAM, Mass., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive breast cancers, announced today that it will host its first Investor Day on Tuesday, November 17 from 8:00 a.m. to 11:30 a.m. EST in New York City.

A live webcast of the presentations will be available from the "Events & Presentations" page of Radius’ website at http://ir.radiuspharm.com/events.cfm. A replay will also be available approximately two hours after completion of the event and will be archived on the Company's website.

Event
Date: November 17, 2015
Time: 8:00 a.m. – 11:30 a.m. EST
Breakfast and Registration: 8:00 a.m. – 8:30 a.m. EST
Program and Webcast: 8:30 a.m. – 11:30 a.m. EST

Presenters:

Robert E. Ward: President and Chief Executive Officer

Gary Hattersley: Chief Scientific Officer

Lorraine Fitzpatrick: Chief Medical Officer

Dinesh Purandare: SVP, Global Head of Oncology

Greg Williams: Chief Development Officer

David Snow: Chief Commercial Officer 

About Radius Health

Radius is a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers. Radius' lead development candidate is the investigational drug abaloparatide for subcutaneous injection, currently in Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with severe osteoporosis. The Radius clinical portfolio also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug RAD1901 for potential use in hormone driven, or hormone resistant, metastatic breast cancer, and vasomotor symptoms. www.radiuspharm.com

CONTACT:
Investor Relations
Barbara Ryan
203-274-2825
Bryan@radiuspharm.com

Media
Alice Pomponio
617-551-4099
apomponio@radiuspharm.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.